Probiotics for Infant Eczema: What 12 RCTs Show and Which Strain Actually Matters

Atopic dermatitis (eczema) affects roughly 15–20% of infants in high-income countries, often as the first sign of an "atopic march" toward food allergy and asthma. The hygiene hypothesis sparked decades of probiotic research — could supplementation early in life help? After more than a hundred trials, the answer is more specific than the marketing suggests: certain strains, given in certain windows, may modestly reduce the risk of developing eczema. Treating established eczema is a different question with weaker evidence.

Prevention: where the evidence is strongest

The 2015 World Allergy Organization guideline conditionally recommends probiotic use in pregnancy and breastfeeding for women whose infants are at high risk of allergy, and in infants at high risk of allergy themselves [1]. The recommendation is based on a meta-analysis of more than two dozen randomised trials showing roughly a 20% relative reduction in incident eczema by age 2–4 years. The strains with the most consistent evidence are Lactobacillus rhamnosus GG (LGG) and certain Bifidobacterium strains, used during the third trimester and the first months of infant life [2]. Effect on later asthma or food allergy is less clear.

Treatment of existing eczema: weaker

A 2018 Cochrane review of 39 trials (over 2,500 infants and children) examined probiotics as treatment for established eczema. The effect on SCORAD (a standardised severity score) was small and the certainty of the evidence was low [3]. Probiotics were not effective at reducing itching or improving quality of life. The implication: prevention before symptoms appear is the place where evidence supports use; once eczema is established, probiotics are unlikely to be a useful primary treatment.

Strain matters more than "probiotics" as a category

Pooling all probiotics together obscures real strain-specific differences. L. rhamnosus GG, L. reuteri DSM 17938, L. paracasei, and B. lactis Bb-12 have the most prevention data; mixed multi-strain formulations have less consistent results [4]. Buying "a probiotic" without checking the strain is no different from buying "an antibiotic" without checking which one — most retail formulations do not list specific strains or give doses that match published trials.

Dosing and timing in trials

Effective trials typically use 10⁹ to 10¹⁰ CFU per day, started at 32–36 weeks of pregnancy in the mother, continued through breastfeeding, and given to the infant for the first six months [5]. Shorter or later courses have produced smaller and less consistent effects. Probiotic prevention is essentially a perinatal-window intervention.

Safety and where caution is warranted

For healthy term infants, established probiotic strains are well tolerated. There are well-documented case reports of probiotic-associated bacteremia and fungemia in premature infants, immunocompromised children, and infants with central venous catheters [6]. These groups should not receive probiotics outside neonatal-ICU protocols developed for them.

Practical takeaway

If a family has a strong personal or family history of atopic disease and a baby is on the way, talking with the obstetric and paediatric team about L. rhamnosus GG or B. lactis Bb-12 in the third trimester and first months of life is reasonable, evidence-supported, and low risk. For an infant with established eczema, probiotics are not a substitute for emollients, low-potency topical steroids when needed, and bath strategies. Strain identity, dose, and timing all matter more than the word "probiotic" on the label.

Where the field has moved beyond "any probiotic"

Earlier paediatric probiotic literature lumped strains together. Newer reviews increasingly stratify by strain, dose, formulation, and timing — recognising that L. rhamnosus GG in pregnancy through breastfeeding has different effects than a generic multi-strain capsule started at six months of age. The European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) has issued strain-specific recommendations for indications including infectious diarrhoea, antibiotic-associated diarrhoea, and infant colic — and explicitly cautions against extrapolation across strains.

What dietary patterns sit alongside probiotic decisions

The microbiome an infant develops in the first year is shaped by mode of delivery (vaginal versus caesarean), feeding (breast versus formula), antibiotic exposure, household pets and siblings, and complementary food introduction. None of these are erased by adding a probiotic; the probiotic is a small input alongside large structural ones. Families considering probiotic supplementation in pregnancy should be having parallel conversations about realistic delivery preferences, breastfeeding plans, and antibiotic stewardship — those choices have larger downstream effects on infant microbial development.